Pharmaceuticals & Agriculture / Life Sciences Conglomerate
Strategic Profile
Bayer's stock has recovered significantly, with BofA Securities raising its 12-month price target to €55 from €35 following greater confidence after a U.S. Supreme Court development related to glyphosate litigation. The company projects a return to profit growth from 2026 onwards driven by a robust pharmaceutical pipeline, crop science optimizations, and internal restructuring aimed at significant savings.
Cyborg Score Rationale
Bayer demonstrates strong fundamentals with a robust pharma pipeline and diversified revenue streams across healthcare and agriculture. However, persistent litigation risks, debt challenges, and recent profit pressures constrain upside, with recovery dependent on successful pipeline execution and litigation resolution.
Top Insights
Stock price recovery of ~90% from 2024 lows, trading near €45 in February 2026 after reaching €19-22 range in early 2025
Strong pharmaceutical pipeline with new product launches positioned to offset patent expirations and drive sustainable growth
Litigation exposure, particularly glyphosate-related cases, remains a key valuation variable with substantial uncertainty reflected in analyst price targets ranging €23-€58
Analyst consensus revisions suggest growing confidence in operational turnaround and deleveraging trajectory, though debt remains elevated constraint